<DOC>
	<DOC>NCT01276509</DOC>
	<brief_summary>Adults with Crohn's disease that is clinically active despite conventional treatment will be eligible for this study. Patients may receive one of three doses of PF-00547659 (experimental drug) or placebo (inactive drug). Disease activity will be measured every two weeks.</brief_summary>
	<brief_title>Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Subjects must have failed or are intolerant to antiTNFs and/or immunosuppressants (AZA, 6MP, and/or MTX). hsCRP greater than 3mg/L Ulcerations demonstrated by colonoscopy performed during screening or 8 weeks prior to screening Pregnant or breast feeding Short bowel syndrome due to multiple small bowel resections Presence of a stoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Crohn's disease Safety Efficacy Pharmacokinetics Pharmacodynamics Crohn's Disease Activity Index (CDAI)</keyword>
</DOC>